Tolerability Study of Xerecept® in Pediatric Patients

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

October 31, 2012

Study Completion Date

March 31, 2013

Conditions
Brain EdemaBrain Tumor
Interventions
DRUG

XERECEPT

BID dosing, subcutaneous for 1 year

Trial Locations (2)

60614

Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago

02115

Dana-Farber Cancer Institute Pediatric Oncology, Boston

All Listed Sponsors
lead

Celtic Pharma Development Services

INDUSTRY